:: Home   :: Contact ICare   :: Site Map          
 | Home | About ICare | Research | CTR Library | Register | Contact ICare
Gastric/Stomach Cancer News
Breast Cancer Breakthrough News
  Jan 16, 2008
ASCO GI: Nutritional Support May Improve Survival in Esophageal Cancer
  By Charles Bankhead, Staff Writer, MedPage Today

SAN FRANCISCO, Jan. 16 -- Locally advanced esophageal cancer may have a better outcome if radiation therapy is augmented by nutritional support, a retrospective analysis suggested.   <READ MORE>

  Jan 16, 2008
ASCO GI: Bevacizumab-Taxane Duo Enhances Response in Gastroesophageal Cancer
  By Charles Bankhead, Staff Writer, MedPage Today

SAN FRANCISCO, Jan. 16 -- Two thirds of patients with metastatic gastroesophageal cancer responded to a regimen of docetaxel-based (Taxotere) chemotherapy plus bevacizumab (Avastin), a small trial showed.  <READ MORE>

  Jan 16, 2008
ASCO GI: Advanced Esophageal Cancer Benefits from Multimodality Neoadjuvant Therapy
  By Charles Bankhead, Staff Writer, MedPage Today

SAN FRANCISCO, Jan. 16 -- Patients with locally advanced esophageal and gastric cancer had a high rate of pathologic complete response and resectability with neoadjuvant cetuximab (Erbitux) and chemoradiation, according to a study reported here.   <READ MORE>

  Aug 1, 2008
H. pylori Treatment Reduces Metachronous Stomach Cancer Risk
  By Charles Bankhead, Staff Writer, MedPage Today

SAPPORO, Japan, Aug. 1 -- After resected early-stage gastric cancer, prophylactic eradication of Helicobacter pylori significantly reduces the risk of metachronous disease, investigators here reported.  <READ MORE>

  May 16, 2008
ASCO: Missing Mutations Hold Clue to Imatinib (Gleevec) GIST Resistance
  By Michael Smith, North American Correspondent, MedPage Today

PHILADELPHIA, May 16 -- Some imatinib (Gleevec)-resistant patients with gastrointestinal stromal tumors (GIST) don't respond because they are missing the mutations in two genes that are usually integral to the disease.  <READ MORE>

  Mar 12, 2008
Chemotherapy Offers Little Benefit for Localized Stomach Cancer 
  By Crystal Phend, Staff Writer, MedPage Today

FLORENCE, Italy, March 12 -- Combination chemotherapy may not improve survival for nonmetastatic gastric cancer after surgery, results of a randomized clinical trial suggested.  <READ MORE>

  Jan 28, 2008
ASCO GI: Sunitinib Shows Good Real-World Imatinib-Resistant GIST Results 
  By Ed Susman, Contributing Writer, MedPage Today

ORLANDO, Jan. 28 -- Patients with gastrointestinal stromal tumor (GIST) who didn't make it into the formal phase III trials of sunitinib (Sutent) for imatinib (Gleevec)-resistant disease did well anyway, investigators reported here.  <READ MORE>

  Jan 25, 2008
ASCO GI: Serum Imatinib (Gleevec) Levels Predict GIST Response
  By Peggy Peck, Executive Editor, MedPage Today

ORLANDO, Jan.25 -- Higher circulating levels of imatinib (Gleevec) correlated with better clinical responses in patients with gastrointestinal stromal tumors (GIST), but proper initial doses were unpredictable, a researcher reported here. <READ MORE>

  Aug 14, 2007
Gastric Cancer Rate Should Drop Significantly
  By Charles Bankhead, Staff Writer, MedPage Today

ROTTERDAM, The Netherlands, Aug. 14 -- The incidence of gastric cancer in developed Western nations will decrease by 24% during the next 10 years, investigators have concluded. <READ MORE>


:: 12 Element Approach ::
Explore and supplement your therapy with ICare's unique 12-Element approach to Patient Survival.

:: Breakthrough News ::
Breaking news on research for gentler, more effective therapies and information on lifesaving treatment options.

:: ICare Bulletin Board ::
View pertinent information regarding meetings and events pertaining to cancer patients. This is also a resource for contacting other patients about information and treatment options.

Copyright ⓒ ICare.  All rights reserved.